2022

  1. Head-to-Head Comparison of 10 Plasma Phospho-Tau Assays in Prodromal Alzheimer’s Disease
    Janelidze, Shorena, Divya Bali, Nicholas J Ashton, Nicolas R Barthélemy, Jeroen Vanbrabant, Erik Stoops, Eugeen Vanmechelen, et al. “Head-to-Head Comparison of 10 Plasma Phospho-Tau Assays in Prodromal Alzheimer’s Disease.” Brain, September 10, 2022, awac333.
  2. Effect of race on prediction of brain amyloidosis by plasma Aβ42/Aβ40, phosphorylated tau, and neurofilament light
    Schindler SE, Karikari TK, Ashton NJ, Henson RL, Yarasheski KE, West T, Meyer MR, Kirmess KM, Li Y, Saef B, Moulder KL, Bradford D, Fagan AM, Gordon BA, Benzinger TLS, Balls-Berry J, Bateman RJ, Xiong C, Zetterberg H, Blennow K, Morris JC. Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light. Neurology. 2022 Jul 19;99(3):e245-e257. doi: 10.1212/WNL.0000000000200358. Epub 2022 Apr 21. PMID: 35450967.
  3. Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity
    Zicha S, Bateman RJ, Shaw LM, Zetterberg H, Bannon AW, Horton WA, Baratta M, Kolb HC, Dobler I, Mordashova Y, Saad ZS, Raunig DL, Spanakis EM, Li Y, Schindler SE, Ferber K, Rubel CE, Martone RL, Weber CJ, Edelmayer RM, Meyers EA, Bollinger JG, Rosenbaugh EG, Potter WZ; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium Plasma Aβ as a Predictor of Amyloid Positivity in Alzheimer’s Disease Project Team. Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity. Alzheimers Dement. 2022 Jul 12. doi: 10.1002/alz.12697. Epub ahead of print. PMID: 35820077.
  4. CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease
    Strain JF, Barthelemy N, Horie K, Gordon BA, Kilgore C, Aschenbrenner A, Cruchaga C, Xiong C, Joseph-Mathurin N, Hassenstab J, Fagan AM, Li Y, Karch CM, Perrin RJ, Berman SB, Chhatwal JP, Graff-Radford NR, Mori H, Levin J, Noble JM, Allegri R, Schofield PR, Marcus DS, Holtzman DM, Morris JC, Benzinger TLS, McDade EM, Bateman RJ, Ances BM. CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. Neurobiol Dis. 2022 Jun 15;168:105714. doi: 10.1016/j.nbd.2022.105714. Epub 2022 Mar 28. PMID: 35358703.
  5. Recapitulation of endogenous 4R tau expression and formation of insoluble tau in directly reprogrammed human neurons
    Capano LS, Sato C, Ficulle E, Yu A, Horie K, Kwon JS, Burbach KF, Barthélemy NR, Fox SG, Karch CM, Bateman RJ, Houlden H, Morimoto RI, Holtzman DM, Duff KE, Yoo AS. Recapitulation of endogenous 4R tau expression and formation of insoluble tau in directly reprogrammed human neurons. Cell Stem Cell. 2022 Jun 2;29(6):918-932.e8. doi: 10.1016/j.stem.2022.04.018. PMID: 35659876; PMCID: PMC9176216.
  6. A Method For The Quantitation Of The Metabolism Of Soluble Amyloid Precursor Protein Isoforms Using A Stable Isotope Labeling Kinetics Approach Paired With Tandem Mass Spectrometry
    Justyna A. Dobrowolska Zakaria, Randall J. Bateman, Monika Lysakowska et al. A Method For The Quantitation Of The Metabolism Of Soluble Amyloid Precursor Protein Isoforms Using A Stable Isotope Labeling Kinetics Approach Paired With Tandem Mass Spectrometry, 24 February 2022, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-1321675/v1]
  7. A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer’s disease
    Budelier MM, He Y, Barthelemy NR, Jiang H, Li Y, Park E, Henson RL, Schindler SE, Holtzman DM, Bateman RJ. A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer’s disease. Brain Commun. 2022 Feb 22;4(2):fcac045. doi: 10.1093/braincomms/fcac045. PMID: 35415607; PMCID: PMC8994116.
  8. Validation of plasma amyloid-β 42/40 for detecting Alzheimer disease amyloid plaques
    Li Y, Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Weiner MW, Shaw LM, Masters CL, Fowler CJ, Trojanowski JQ, Korecka M, Martins RN, Janelidze S, Hansson O, Bateman RJ. Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques. Neurology. 2022 Feb 15;98(7):e688-e699. doi: 10.1212/WNL.0000000000013211. Epub 2021 Dec 14. PMID: 34906975; PMCID: PMC8865895.
  9. Importance of CSF-based Aβ clearance with age in humans increases with declining efficacy of blood-brain barrier/proteolytic pathways
    Elbert DL, Patterson BW, Lucey BP, Benzinger TLS, Bateman RJ. Importance of CSF-based Aβ clearance with age in humans increases with declining efficacy of blood-brain barrier/proteolytic pathways. Commun Biol. 2022 Jan 27;5(1):98. doi: 10.1038/s42003-022-03037-0. PMID: 35087179; PMCID: PMC8795390.
  10. Astrocytic 4R tau expression drives astrocyte reactivity and dysfunction.
    Ezerskiy LA, Schoch KM, Sato C, Beltcheva M, Horie K, Rigo F, Martynowicz R, Karch CM, Bateman RJ, Miller TM.
    JCI Insight. 2022 Jan 11;7(1):e152012. doi: 10.1172/jci.insight.152012.
    PMID: 34874917 Free PMC article.
  11. Plasma MCP-1 and changes on cognitive function in community-dwelling older adults.
    Sanchez-Sanchez JL, Giudici KV, Guyonnet S, Delrieu J, Li Y, Bateman RJ, Parini A, Vellas B, de Souto Barreto P; MAPT/DSA Group.
    Alzheimers Res Ther. 2022 Jan 7;14(1):5. doi: 10.1186/s13195-021-00940-2.
    PMID: 34996522 Free PMC article.
  12. Does Data-Independent Acquisition Data Contain Hidden Gems? A Case Study Related to Alzheimer’s Disease.
    Hubbard EE, Heil LR, Merrihew GE, Chhatwal JP, Farlow MR, McLean CA, Ghetti B, Newell KL, Frosch MP, Bateman RJ, Larson EB, Keene CD, Perrin RJ, Montine TJ, MacCoss MJ, Julian RR.
    J Proteome Res. 2022 Jan 7;21(1):118-131. doi: 10.1021/acs.jproteome.1c00558. Epub 2021 Nov 24.
    PMID: 34818016 Free PMC article.
  13. Interactions between weight loss and plasma neurodegenerative markers for determining cognitive decline among community-dwelling older adults.
    Giudici KV, Guyonnet S, Morley JE, Nguyen AD, Aggarwal G, Parini A, Li Y, Bateman RJ, Vellas B, Barreto PS; MAPT/DSA group.
    J Gerontol A Biol Sci Med Sci. 2022 Jan 16:glac015. doi: 10.1093/gerona/glac015. Online ahead of print.
    PMID: 35034116
  14. Site-Specific Cerebrospinal Fluid Tau Hyperphosphorylation in Response to Alzheimer’s Disease Brain Pathology: Not All Tau Phospho-Sites are Hyperphosphorylated.
    Barthélemy NR, Toth B, Manser PT, Sanabria-Bohórquez S, Teng E, Keeley M, Bateman RJ, Weimer RM, Wildsmith KR.
    J Alzheimers Dis. 2022;85(1):415-429. doi: 10.3233/JAD-210677.
    PMID: 34806603
  15. Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer’s disease: cross-sectional and longitudinal analyses of an observational study.
    Chhatwal JP, Schultz SA, McDade E, Schultz AP, Liu L, Hanseeuw BJ, Joseph-Mathurin N, Feldman R, Fitzpatrick CD, Sparks KP, Levin J, Berman SB, Renton AE, Esposito BT, Fernandez MV, Sung YJ, Lee JH, Klunk WE, Hofmann A, Noble JM, Graff-Radford N, Mori H, Salloway SM, Masters CL, Martins R, Karch CM, Xiong C, Cruchaga C, Perrin RJ, Gordon BA, Benzinger TLS, Fox NC, Schofield PR, Fagan AM, Goate AM, Morris JC, Bateman RJ, Johnson KA, Sperling RA; Dominantly Inherited Alzheimer’s Network Investigators.
    Lancet Neurol. 2022 Feb;21(2):140-152. doi: 10.1016/S1474-4422(21)00375-6.
    PMID: 35065037